Chronic Hepatitis C virus infection in Swiss primary care practices: Low case loads—high barriers to treatment?

References

• World Health Organization. Initiative for Vaccine Research. Viral Cancers, Hepatitis C. Available at: http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html (accessed 25 July 2010).
   Google Scholar
• Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2002;345:41–52.
   Google Scholar
• Sagmeister M, Renner EL, Mullhaupt B, Wong JB. Simulation of hepatitis C based on a mandatory reporting system. Eur J Gastroenterol Hepatol. 2002;14:25–34.
   PubMed Web of Science ®Google Scholar
• Patel K, Muir AJ, McHutchison J. Diagnosis and treatment of chronic hepatitis C infection. Br Med J. 2006;332: 1013–7.
   PubMed Web of Science ®Google Scholar
• Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003;362:2095–100.
   PubMed Web of Science ®Google Scholar
• Kanwal F, Hoang T, Spiegel BM, Eisen S, Dominitz J, Gifford A, . Predictors of treatment in patients with chronic hepatitis C infection—role of patient versus nonpatient factors. Hepatology 2007;46:1741–9.
   PubMedGoogle Scholar
• Bini EJ, Bräu N, Currie S, Shen H, Anand BS, Hu KQ, . Prospective multicenter study of eligibility for antiviral therapy among 4,084 US veterans with chronic hepatitis C infection. Am J Gastroenterol. 2005;100: 1772–9.
   PubMed Web of Science ®Google Scholar
• Butt AA, Justice AC, Skanderson M, Rigsby M, Good CB, Kwoh CK, . Rate and predictors of treatment prescription for hepatitis C. Gut 2007;56:385–9.
   PubMed Web of Science ®Google Scholar
• Bruggmann P, Falcato L, Dober S, Helbling B, Keiser O, Negro F, . Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepatitis 2008;15:747–52.
   PubMed Web of Science ®Google Scholar
• Sylvestre DL. Treating hepatitis C in methadone maintenance patients: An interim analysis. Drug Alcohol Depend. 2002;67:117–23.
   PubMed Web of Science ®Google Scholar
• Van Thiel DH, Friedlander L, Molloy PJ, Fagiuoli S, Kania RJ, Caraceni P. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have psychiatric illness. Eur J Gastroenterol Hepatol. 1995;7:165–8.
   PubMed Web of Science ®Google Scholar
• National Institute of Health. NIH Consensus Statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1–46.
   Google Scholar
• Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. the 2002 French consensus. Gut 2003;52: 1784–7.
   PubMed Web of Science ®Google Scholar
• Trutmann M. Magna com cura. The current situation of medical primary care in Switzerland. Physician demographics and training reform (in German). Swiss Conference of the Cantonal Ministers of Public Health (GDK); 2007. Available at: http://swtr.ch/d/ablage/dokumentation/swtr_demmed2007D.pdf (accessed 12 March 2009).
   Google Scholar
• D'Souza RF, Glynn MJ, Alstead E, Osonayo C, Foster GR. Knowledge of chronic hepatitis C among East London primary care physicians following the Department of Health's educational campaign. QJ Med. 2004;97:331–6.
   Google Scholar
• Fages M, Fabbro-Peray P, Daunes JP, Ribard C, Morrut. Access to electronic hepatitis C medical files by general practitioners. Gastroenterol Clin Biol. 2008;32:224–31.
   PubMedGoogle Scholar
• SevHEP. (Swiss experts for viral hepatitis). Available at: http://www.sevhep.ch. (accessed 15 July 2010).
   Google Scholar
• Prasad L, Spicher VM, Zwahlen M, Rickenbach M, Helbling B, Negro F, . Swiss Hepatitis C Cohort Study Group. Cohort Profile: The Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol. 2007;36:731–7.
   PubMedGoogle Scholar
• Seeff LB, Natural history of chronic hepatitis C. Hepatology 2002;36(Suppl. 1):S35–46.
   PubMedGoogle Scholar
• Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(Suppl.):S237–44.
   PubMedGoogle Scholar
• Bagheri H, Fouladi A, Barange K, Lapeyre-Mestre M, Payen JL, Montastruc JL, . Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy. Pharmacotherapy 2004;24:1546–53.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Alberti A, Rosenberg W, Marcellin P, Diago M, Negro F, . Review article: Management of patients with chronic hepatitis C virus infection and “normal” alanine aminotransferase activity. Aliment Pharmacol Ther. 2006; 24:1133–49.
   PubMedGoogle Scholar
• Shiffman ML, Stewart CA, Hofmann CM Contos MJ, Luketic VA, Sterling RK, . Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: Comparison of hepatic histology and response to interferon therapy. J Infect Dis. 2000;182:1595–01.
   PubMedGoogle Scholar
• Montano D, Phillips W. Cancer screening by primary care physicians: A comparison of rates obtained from physician self-report, patient survey, and chart audit. Am J Public Health 1995;85:795–800.
   PubMed Web of Science ®Google Scholar